HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that Igor Gonda , Aradigm's President and Chief Executive Officer, will present an overview of the Company at the Stifel Healthcare Conference 2014 at the New York Palace Hotel in New York, New
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2014 . Total revenue was approximately $6.6 million for the third quarter of 2014 compared with revenue of approximately
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate, Pulmaquin®, for treatment of non-cystic fibrosis bronchiectasis (non-CF BE)
NASDAQ listing achieved upon completion of reverse split HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2014 . Total revenue was $12.2 million for the second quarter of
Event Will Feature Presentations by KOLs Diana Bilton, MD, and Byron Thomashow , MD HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") announced today that it will host an Analyst Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (non-CF BE) on Tuesday,
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") will host a corporate update conference call at 8:00 am ET ( 5:00 am PT ) on Thursday, June 26, 2014 . The Company will review recent significant milestones, as well as progress with the Pulmaquin® program in
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 ( O nce-daily R
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") announced that it has received the $5 million milestone payment from Grifols S.A. for the dosing of the first patient in the ORBIT-3 ( O nce-daily R espiratory B ronchiectasis I nhalation T
Pulmaquin designated as a QIDP for Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Chronic Lung Infections with Pseudomonas aeruginosa HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced that the U.S.
Completion of Royalty Assignment Eliminates All Debt HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2014 . Total revenue was $6.6 million for the first quarter of
Aradigm's Pulmaquin - A Potential New Therapy to Treat an Unmet Medical Need in Patients with Severe Respiratory Disease HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-3 ( O nce-daily
HAYWARD, Calif. --(BUSINESS WIRE)-- Scientists from the Oregon State University , Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the "Company") demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus , Aradigm's
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013 . Fourth Quarter 2013 Results The Company recorded $4.6 million in revenue in the fourth quarter of 2013 compared
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 16 th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014 , at 10:30 a.m. ET .
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014 , at 11: 30 a.m. Pacific time.
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today announced that Juergen Froehlich , MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2013 . Total revenue was approximately $4.6 million for the third quarter of 2013 compared with revenue of
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell . Mr.
INDIANAPOLIS & HAYWARD, Calif. --(BUSINESS WIRE)-- Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc. ), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota , Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons
